DAVITA INC. (NYSE:DVA) Files An 8-K Other Events

37

DAVITA INC. (NYSE:DVA) Files An 8-K Other Events
Item 8.01. Other Events.

On October 10, 2017, the Board of Directors of DaVita Inc. (the “Company”) increased the authorization under the Company’sshare repurchaseprogram to an aggregate of $1,500,000,000 in repurchasing authority (the “New Repurchase Program”). The amount of shares of common stock authorized to be repurchased under the New Repurchase Program includes the amount remaining under the Company’s existing stock repurchase program (the “Existing Repurchase Program”) authorized on July 13, 2016. The Existing Repurchase Program and the New Repurchase Program do not have an expiration date and do not obligate the Company to purchase any shares. Repurchases under the New Repurchase Program and the Existing Repurchase Program may take place in the open market or privately negotiated transactions, including without limitation, acceleratedshare repurchasetransactions, derivative transactions, tender offers, under Rule 10b5-1 plans or any combination of the foregoing.There can be no assurance as to the precise number of shares that will be repurchased under the Existing Repurchase Program or the New Repurchase Program, the aggregate dollar amount of the shares purchased, or the ultimate disposition of the shares purchased (re-issued, retained in treasury and/or retired). Depending on market conditions, regulatory, legal and contractual requirements and other factors, repurchases may be made at any time or from time to time, without prior notice. The Company may suspend or discontinue the Existing Repurchase Program and/or the New Repurchase Program, or increase or decrease the amount of shares authorized to be repurchased thereunder, at any time.

This Current Report on Form 8-K contains statements that are forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended and Section21E of the Securities Exchange Act of 1934, as amended. The Company intends these forward-looking statements to be covered by the safe harbor provisions for such statements. All statements that do not concern historical facts are forward-looking statements and include, among other things, statements about our expectations, beliefs, intentions and/or strategies for the future. These forward-looking statements include statements regarding anticipated repurchasing transactions, and the Company's future operations, financial condition and prospects. These statements can sometimes be identified by the use of forward-looking words such as “may,” “believe,” “will,” “should,” “could,” “would,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “continue,” “seek,” “forecast,” or “intend” or other similar words or expressions of the negative thereof. These statements involve substantial known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those described in the forward-looking statements, including, but not limited to the risk factors set forth in the Company’s Annual Report on Form 10-K for the year ended December31, 2016, and subsequent quarterly reports on Form 10-Q. These forward-looking statements should be considered in light of these risks and uncertainties. All forward-looking statements in this report are based on information available to the Company on the date of this report. The Company undertakes no obligation to publicly update or revise any of these forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise.


About DAVITA INC. (NYSE:DVA)

DaVita Inc., formerly DaVita HealthCare Partners Inc., is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. The Company’s segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. The Company’s Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD). HCP division is a patient and physician-focused integrated health care delivery and management company.

An ad to help with our costs